Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lifecore Biomedical's Intergel

This article was originally published in The Gray Sheet

Executive Summary

Adhesion prevention solution shows 54% reduction (p=0.004) of adhesion formation in the abdominal cavities of 50 female laparoscopic abdominal surgery patients in a pilot clinical trial, the company tells investors at a June 9 session of the Piper Jaffray conference in Minneapolis. Twenty four abdominal sites are included as primary endpoints. The company expects to meet with FDA in the next month to finalize enrollment criteria to commence a pivotal laparoscopy study. Intergel was introduced in Europe May 5 by exclusive worldwide distributor Johnson & Johnson's Ethicon. U.S. sales are expected to begin in late 1999
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel